MiRNA-21: A key to controlling the cardiac fibroblast compartment?

Cardiovascular Research

Volumn 82, Issue 1, 2009, Pages 1-3

  Haghikia, Arash ^a   Hilfiker Kleiner, Denise ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

METALLOPROTEINASE; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

EDITORIAL; FIBROBLAST; GENE EXPRESSION; HEART; HEART INFARCTION; HUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RNA TRANSLATION; SIGNAL TRANSDUCTION;

ANIMALS; FIBROBLASTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MATRIX METALLOPROTEINASE 2; MICE; MICRORNAS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; TIME FACTORS;

EID: 62349119294     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp058     Document Type: Editorial

References (21)

1. Braunwald E, Rutherford JD. Reversible ischemic left ventricular dysfunction: evidence for the 'hibernating myocardium'. J Am Coll Cardiol 1986;8:1467-1470.
2. Bolli R, Marban E. Molecular and cellular mechanisms of myocardial stunning. Physiol Rev 1999;79:609-634.
3. Morley ME, Riches K, Peers C, Porter KE. Hypoxic inhibition of human cardiac fibroblast invasion and MMP-2 activation may impair adaptive myocardial remodelling. Biochem Soc Trans 2007;35:905-907.
4. Roy S, Khanna S, Hussain SR, Biswas S, Azad A, Rink C et al. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast MMP2 via PTEN. Cardiovasc Res 2009;82:21-29.
5. Ambros V. The evolution of our thinking about microRNAs. Nat Med 2008;14:1036-1040.
6. Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 2007;129:1401-1414.
7. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M et al. Silencing ofmicroRNAs in vivo with 'antagomirs'. Nature 2005;438:685-689.
8. Scherr M, Venturini L, Battmer K, Schaller-Schoenitz M, Schaefer D, Dallmann I et al. Lentivirus-mediated antagomir expression for specific inhibition of miRNA function. Nucleic Acids Res 2007;35:e149.
9. van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, Gerard RD et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA 2006;103:18255-18260.
10. Care A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med 2007;13:613-618.
11. da Costa Martins PA, Bourajjaj M, Gladka M, Kortland M, van Oort RJ, Pinto YM et al. Conditional dicer gene deletion in the postnatal myocardium provokes spontaneous cardiac remodeling. Circulation 2008;118:1567-1576.
12. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008;456:980-984.
13. Oudit GY, Penninger JM. Cardiac regulation by phosphoinositide 3-kinases and PTEN. Cardiovasc Res, Published online ahead of print 30 January 2009.
14. Chow AK, Cena J, Schulz R. Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature. Br J Pharmacol 2007;152:189-205.
15. Cheung PY, Sawicki G, Wozniak M, Wang W, Radomski MW, Schulz R. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 2000;101:1833-1839.
16. Hudson MP, Armstrong PW, Ruzyllo W, Brum J, Cusmano L, Krzeski P et al. Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial. J Am Coll Cardiol 2006;48:15-20.
17. Spinale FG, Escobar GP, Hendrick JW, Clark LL, Camens SS, Mingoia JP et al. Chronic matrix metalloproteinase inhibition following myocardial infarction in mice: differential effects on short and long-term survival. J Pharmacol Exp Ther 2006;318:966-973.
18. Vanhoutte D, Schellings M, Pinto Y, Heymans S. Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window. Cardiovasc Res 2006;69:604-613.
19. van Rooij E, Olson EN. Searching for miR-acles in cardiac fibrosis. Circ Res 2009;104:138-140.
20. Castanotto D, Rossi JJ. The promises and pitfalls of RNA-interference- based therapeutics. Nature 2009;457:426-433.
21. van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA 2008;105:13027-13032.